Pfizer and BioNtech counter-sue Moderna over Covid-19 vaccine patents

The pharma, in arms. The American pharmaceutical company and its German partner have responded to the lawsuit filed by Moderna for “violate” its mRNA patent on the Covid-19 vaccine with a counterclaim against the pharmaceutical companyas reported Reuters.

Now, both Pfizer and BioNtech say Moderna’s patents are invalidas they attempt to dismiss the appeal the company filed in August. Pfizer had already assured then that it trusted his intellectual property and that he would “strongly defend” himself against Moderna’s claims.

Four months after the first lawsuit, both companies are saying so they developed their vaccine independently and that Moderna’s claim is “historical revisionism”. They also claim that the company has discredited the contributions of its scientists, as well as those of researchers at the US National Institutes of Health.

In August, Moderna filed a lawsuit in a Massachusetts (US) court and another in Düsseldorf (Germany). The company said Pfizer and BioNTech’s Comirnaty Covid vaccine infringed on patents Moderna filed between 2010 and 2016 covering Moderna’s core mRNA technology.

The company underlined this when the pandemic broke out, neither Pfizer nor BioNTech had the technology to develop a vaccine with mRNA for infectious diseases and “knowingly followed Moderna’s path to develop a vaccine.”

Through the Covid-19 vaccine, Pfizer expects to make more than $30,000 million in 2022 and accounted for half of its revenue in the last year. On request, Moderna is seeking financial compensation from Pfizer “for its continued use of its patents for its own benefit”.

Moderna has revised its revenue forecast downwards in 2022, due to the agreements inked to advance the sale of its Covid-19 vaccine following the delay related to short-term supply constraints.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick